deltatrials
Completed PHASE2 NCT00383149

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Sponsor: R-Pharm

Conditions Metastatic Pancreatic Cancer
Interventions Cetuximab Ixabepilone
Updated 8 times since 2017 Last updated: Feb 9, 2016 Started: Jan 31, 2007 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

A PHASE2 clinical study on Metastatic Pancreatic Cancer, this trial is completed. The trial is conducted by R-Pharm and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • R-Pharm
Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ann Arbor, United States
  • • Columbia, United States
  • • Detroit, United States
  • • Greenville, United States
  • • Jacksonville, United States
  • • Miami, United States
  • • Morgantown, United States
  • • Seattle, United States
  • • Washington D.C., United States